Durga Mata, the mother Hindu goddess, is a 90% Indica strain with roots originating in the natural landraces of South Asia. The moss green arrow-shaped buds are speckled with amber hair and coated in a sweet resin from a myriad of crystal trichomes. The earthy, sweet and citrusy aroma is reminiscent of Italian Panettone.
| Potency: | THC: 20.3%, CBD< 0.1% |
|---|---|
| Format: | Dried Cannabis, 5 g |
| Terpene profile: | Terpinolene, limonene and myrcene |
| Price: | $8.50 per gram |
Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.
Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.
Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.
He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.
Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.